Sermaglutide is a long-acting GLP-1 receptor agonist for the treatment of type 2 diabetes, developed by Novo Nordisk, a Danish pharmaceutical company. It regulates blood sugar by stimulating insulin secretion and inhibiting glucagon secretion, with the convenience of subcutaneous injection once a week, and can reduce the risk of cardiovascular events.